Pre-approval clinical development phases and concepts

Before any clinical study can be conducted in children, a robust preclinical programme is required to characterise the safety, pharmacokinetics, and pharmacodynamics of the investigational product. In paediatric drug development, juvenile animal studies – which use animal models at developmental stages analogous to the human paediatric age groups of interest – are often required to assess developmental toxicity that may not be apparent in adult animal models. The design and interpretation of juvenile animal studies is described in ICH guideline S11, which provides guidance on when such studies are needed, what endpoints to include, and how to translate findings to inform the paediatric clinical programme.
 

Key resources

Background resources

 

Preclinical developmentPreclinical development

Phase I studies in children are designed to characterise the safety, tolerability, and pharmacokinetics (PK) of an investigational product in the paediatric population. Unlike adult Phase I trials, which typically enrol healthy volunteers, paediatric Phase I studies are almost always conducted in children with the disease or condition being investigated, both for ethical reasons (exposing healthy children to investigational products would be difficult to justify) and because disease state may substantially affect drug disposition.

Phase 1 trials in children will generally occur only after the medicinal product has been first investigated in adults. However, phase 1 trials may be done first in children when there is a child-specific severe or life-threatening disease for which there is no effective treatment.

Physiologically based pharmacokinetic (PBPK) modelling is often used to generate the first doses to be tested (Box 4.). PBPK models incorporate what is known about a candidate drug composition with paediatric age-related factors like distribution, metabolism, and clearance. Target drug levels are generally derived from trials in adults, including the minimum levels for efficacy and maximum levels for safety and tolerability.

Box 4: Dose development and selection

Dose selection for paediatric studies typically begins with PK modelling and simulation based on data from adults to predict appropriate starting doses for children. The PK of drugs in children change throughout childhood as organ systems mature. Key development changes affecting drug absorption and disposition include:

  • gastric pH and motility (affecting oral absorption);
  • body composition (affecting volume of distribution);
  • plasma protein building;
  • maturation of metabolic enzymes; and
  • renal function.

Rapid changes in organ and enzyme maturation occurring in early life (i.e., <2 years old); therefore, weight-based or allometric dose scaling from adult data may not be sufficient alone to achieve appropriate drug exposure in young children. This maturation process is even more difficult to predict in pre-term infants which require additional consideration.

Pharmacokinetic studies measure children’s drug levels and help to confirm the optimal dose that maximizes therapeutic benefits while minimizing side-effects or toxicity. Pharmacokinetic samples can be collected using either intensive blood sampling (such as multiple blood draws over a single dosing interval) or sparse blood sample (such as one blood draw between doses or even one blood sample over a treatment course).

Population pharmacokinetic modelling and simulation is a key tool for characterizing and predicting the pharmacokinetic profile of a drug for children; based on available pharmacokinetic data. Population pharmacokinetic models can use both intensive and sparse pharmacokinetic data to fit mathematical models to predict drug concentrations. These pharmacokinetic models can subsequently be used to simulate whether a specific dose of a drug will achieve target exposures.

Key resources

 

Background resources

Phase I: First-in-child studies and dose finding Phase I: First-in-child studies and dose finding

Phase II paediatric trials aim to generate preliminary evidence of efficacy, optimize dosing, and further characterise safety in the target paediatric population.

In paediatrics, phase 1 and 2 (Phase I/II) trials may be combined in some cases for dose finding for rare diseases and childhood cancers, and to accelerate approval and access to urgent, life-saving medicines, such as for HIV in children. Box 5 describes International Maternal Paediatric Adolescent AIDS Clinical Trials Network (IMPAACT) 1093 trial that accelerated approval of a landmark HIV medicine for children by assessing dosing and efficacy across multiple age groups.

Box 5. Case study: IMPAACT P1093 – dolutegravir for infants, children and adolescents with HIV

IMPAACT P1093 is a landmark Phase I/II multicentre, open-label study evaluating the pharmacokinetics, safety, tolerability and antiviral activity of dolutegravir among children with HIV aged 4 weeks to 18 years. Using an age de-escalation design, 181 participants were enrolled across age-defined cohorts, with weight-band dosing of a paediatric dispersible tablet formulation. The study demonstrated that children as young as four weeks could achieve exposure comparable to adults, and its data formed the primary basis for regulatory approval of dolutegravir for children globally, illustrating how well-designed Phase I/II pharmacokinetic studies can directly enable access to effective treatment for children.

Source: Ruel TD, Acosta EP, Liu JP, Gray KP, George K, Montañez N et al. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial. Lancet HIV. 2022;9(5):e332–e340 (https://doi.org/10.1016/S2352-3018(22)00044-3).

 

Phase II: Exploratory efficacy and dose confirmation Phase II: Exploratory efficacy and dose confirmation

When medicines are first evaluated among adults, Phase III efficacy trials may not be needed for children, helping to accelerate the approval and licensing of medicines for children. Paediatric extrapolation is the process of using data from adults or older children to support conclusions about efficacy and/or safety in another paediatric age group to reduce the number and complexity of additional studies required for children (Box 6).

Box 6. Regulatory guidance for using extrapolation

ICH E11A, adopted by the United States Food and Drug Administration in December 2024 and by the EMA in January 2025, is the definitive international framework for paediatric extrapolation. It covers:

  • assessment of disease similarity;
  • evaluation of exposure–response relationships;
  • pharmacokinetic bridging and pharmacodynamic modelling;
  • use of physiologically based pharmacokinetic modelling and Bayesian statistical methods for borrowing strength from adult data; and
  • design of residual paediatric studies within an extrapolation plan.

The scientific validity of extrapolation depends on the assumption that the course of the disease and the response to treatment are sufficiently similar between adults and children. When similarity is high and well evidenced, pharmacokinetic bridging alone, demonstrating that the same drug exposure can be achieved among children as among adults at an appropriate dose, may be sufficient to support approval without any separate efficacy study involving children. When similarity is more uncertain, a pharmacokinetic and pharmacodynamic study or a reduced efficacy study may be needed to supplement pharmacokinetic data. Dedicated paediatric safety data from Phase II studies are usually still required even when efficacy is extrapolated. Extrapolation must be agreed with regulatory authorities and justified early in the paediatric development programme and applied prospectively.

Extrapolation principles have been demonstrated in antibiotics research and have helped to accelerate the development and approval of new agents for treating children for multidrug-resistant pathogens. Fig. 4 illustrates an algorithm for determining whether extrapolating safety or efficacy is a feasible pathway to approval of new chemical entities in paediatric antibiotics research.

Fig. 4. Flow chart illustrating the feasibility of extrapolation for new chemical entities in antibiotics

Fig. 4. Flow chart illustrating the feasibility of extrapolation for new chemical entities in antibiotics

Source: Accelerating optimal approval of priority formulations for antibiotic use in children: meetings report, 7 December 2023 and 19–20 March 2024. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/379572). Licence: CC BY-NC-SA 3.0 IGO.

The use of biomarker endpoints that reflects an earlier phase of disease could also be useful for extrapolation in diseases affecting children and adults. When a validated or well characterized biomarker exists that reflects the mechanism of drug action and correlates with clinical outcome in the reference population, it can serve as a bridge between adult efficacy data and paediatric response. This is especially useful in diseases for which full clinical outcome trials involving children would be very long, very large or ethically difficult.

Key resources

Background resources

Extrapolation and PK bridging Extrapolation and PK bridging

The development of age-appropriate, acceptable and safe pharmaceutical formulations is a fundamental prerequisite for paediatric drug development and is frequently cited as one of the greatest barriers to conducting trials involving young children. Clinical trials of medicinal products involving children need to include medicines that meet the unique formulation needs of children. The development of an economic and effective formulation requires balanced consideration of the risks and benefits of safety, acceptability and access factors (Table 1).

Table 1. Factors to consider in developing paediatric formulations

Patient Acceptability
Dosage considerations The ability of the formulation to be sub-divided without impact on the product's safety and efficacy to allow flexible and optimal dosing to the patient
Dose preparation The requirement for any manipulation or measurement of a quantity of the formulation prior to administration.
Ease of ingestion The ease with which the product may be taken by the patient, including aspects such as palatability, swallowability, size and quantity of solid dosage units, volume of liquid.
Safety
Acceptable tolerability and safety The product should not give rise to an unacceptably high risk of adverse effects, acute toxicity, organ toxicity or GI side effects, which are not directly caused by the API.
Risk of mis-dosing The risk of administration of an incorrect dose, for example by incorrect handling, incorrect measurement and/or incorrect administration of the required dose.
Access
Stability The shelf-life of the product, including in-use if appropriate.
Manufacturing and development complexity How complicated the required development process and manufacturing and packaging operations are, including the need to use specialised, non-routine processes.
Supply chain How the product is stored and transported, including in resource-poor settings.
Relative cost The estimated magnitude of cost of a dosage form compared to the other dosage forms, excluding API cost.

Source: Walsh J, Ranmal SR, Ernest TB, Liu F. Patient acceptability, safety and access: a balancing act for selecting age-appropriate oral dosage forms for paediatric and geriatric populations. Int J Pharm. 2018;536(2):547–562 (https://doi.org/10.1016/j.ijpharm.2017.07.017).

Formulation development should be considered early in the overall drug development programme, with the proposed approach discussed with regulatory agencies when appropriate. Early consideration of the intended paediatric population, dose, dosage form, route of administration, excipients and formulation development strategy can help to identify and address potential barriers before paediatric clinical trials begin.

The physiological and developmental characteristics of children differ from those of adults, and this must be considered in formulation design:

  • Gastric pH and motility differ across age groups, affecting drug absorption.
  • Infants and young children have limited swallowing capability, influencing the suitability of different oral dosage forms.
  • Palatability and taste can influence acceptability and adherence in later development (Phase II/III).
  • Certain excipients widely used in adult formulations may be unsuitable for neonates and young children.

Information on the taste properties of the active pharmaceutical ingredient should, when possible, be generated during Phase I or early adult studies. Early characterization of taste can inform the selection of an age-appropriate dosage form and the need for and approach to taste masking before paediatric clinical development. Excipients should be selected on a case-by-case basis, balancing their functional benefits in the formulation against the potential risks in the intended paediatric population. Particular attention may be needed for neonates and young children for whom the safety profile of some excipients used routinely in adult formulations may not be established or may differ from that of adults.

Sensory evaluation and acceptability studies can help to identify potential barriers to the use of paediatric formulations (see Box 7). Before a clinical trial formulation is finalized, sensory evaluation may be conducted among adult volunteers to characterize taste and assess the effectiveness of taste-masking approaches. When appropriate, acceptability studies in children can subsequently assess palatability and ease of administration using age-appropriate methods. Such assessments should be tailored to the formulation, development stage and intended population; preference testing is not necessarily required in all development programmes. Particular attention to palatability before Phase II and Phase III paediatric trials can help to mitigate the risk of poor adherence compromising study conduct or interpreting the results.

Box 7. Acceptability studies

These studies assess the palatability and ease of administration of a formulation in the target paediatric age group. They may be conducted during clinical development, using age-appropriate assessment tools, such as hedonic scales adapted for different age groups. Their design and conduct require carefully considering the target population, study objectives and ethical requirements. Sensory evaluation among adults may provide complementary information on taste and taste-masking strategies before a formulation is finalized for paediatric clinical trials.

How a medicine is formulated, presented, packaged and administered is also important in paediatric formulation development. The required doses need to be capable of being administered accurately and consistently, which may require an appropriate administration device, such as an oral syringe, dosing cup or other device. Packaging and presentation – whether as a blister pack, bottle, dispersible tablet or sachet – also influence whether a child can receive the correct dose reliably and safely. Presentation affects dosing accuracy, acceptability and adherence as well as the risk of dosing errors or accidental ingestion. It also influences practical factors such as stability, storage, transport and ease of use for caregivers and health-care workers, especially in low-resource settings. Formulations and packaging designed for children’s needs and developed early alongside the clinical programme help to ensure that an efficacious medicine can be used effectively in the real-world settings in which children are treated.

WHO and the EMA have published detailed guidance on developing paediatric formulations. The EMA’s guideline on pharmaceutical development of medicines for paediatric use describes oral and non-oral dosage forms suitable for different paediatric age groups and provides specific requirements for excipient safety in children. WHO’s GAP-f network provides comprehensive resources for paediatric formulation development to researchers, funders and sponsors, including the paediatric quality product profile assessment tool, which evaluates the age-appropriateness and suitability of paediatric formulations for infants and children.

Key resources

Background resources

Paediatric formulation development Paediatric formulation development

The purpose of Phase III is to demonstrate efficacy and extend safety data to support regulatory approval for medicines. Phase III trials may not be required for children if drugs have been proven efficacious for adults before testing involving children. In this case, extrapolating adult efficacy data, supported by​ ​pharmacokinetic and safety bridging studies, can reduce or replace the need for separate Phase III efficacy studies involving children, especially when the disease course and response to therapy are similar for adults and children.

However, when the disease course and outcomes fundamentally differ between adults and children, a Phase III clinical efficacy trials involving children may be necessary and require a different study design and endpoints than the adult protocol. This situation has been noted in several conditions affecting children, including severe malaria, tuberculosis and respiratory syncytial virus.

Phase III trials can be operationally complex and costly. They often require multinational, multicentre designs to achieve adequate sample size within acceptable time frames. These challenges can lead to lengthier trials or even stalled or terminated trials and consequently the lack of ability to approve medicines for children. Phase II trials can also be combined with Phase III trials in adaptive designs that improve efficiency. Box 8 shows an example of a combined Phase II/III trial of coronavirus disease 2019 (COVID-19) vaccine involving children.

Box 8. A combined Phase II/III approach in developing a vaccine for children: study of the mRNA-1273 (Moderna) COVID-19 vaccine among children 6–11 years old

This trial evaluated the mRNA-1273 COVID-19 vaccine for children 6–11 years old using a combined Phase II/III design, with part 1 an open-label dose-selection stage and part 2 an observer-blinded, placebo-controlled expansion of the selected dose. This design reflects the standard age de-escalation approach in paediatric vaccine development: because mRNA-1273 had already been characterized for adolescents and adults, the study did not need to re-establish first-in-human safety but instead could move directly to a single combined protocol that first identified an appropriate dose in the 6- to 11-year age group and then generated safety, reactogenicity and immunogenicity data on that dose in a larger, controlled cohort. Combining what would otherwise be separate Phase II (dose-finding) and Phase III (confirmatory) trials into one seamless protocol avoided the delay of running two sequential studies and enabled the dosing decision made in part 1 to feed directly into the pivotal evaluation in part 2. Consistent with immunobridging approaches used across the paediatric programme, the primary objectives were safety for children and noninferiority of their immune response compared with adults 18–25 years old in a related Phase III trial. This immunobridging strategy, rather than a full efficacy endpoint trial, is a common evidence-generation approach when a product’s mechanism and efficacy have already been established in older age groups, enabling extension to younger children without requiring a comparably large disease-endpoint trial.

Source: Creech CB, Anderson E, Berthaud V, Yildirim I, Atz AM, Melendez Baez I et al. Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age. N Engl J Med. 2022;386(21):2011–2023 (https://doi.org/10.1056/NEJMoa2203315).

When there is a current standard of care for treatment for a paediatric condition, Phase III trials can also serve as an opportunity to assess comparative safety and efficacy between a novel product and existing treatment, leading to both licensing approval of the new product and changes in clinical guidelines. These may be referred to as pragmatic Phase III trials and are especially useful in trials involving children because it embeds additional questions that may help to reduce the need for future studies and therefore reduce the burden on children and families. See the section on post-approval study approaches and practical approaches to study design for how implementation considerations such as cost–effectiveness, acceptability and best clinical use can be integrated into registrational trials. An example of a Phase III trial that integrated cost–effectiveness into the study is the CHAPAS-4 trial for antiretroviral therapy for children living with HIV (link below in key resources).

A major challenge with Phase III trials involving children is identifying and recruiting the eligible population, leading to smaller sample sizes and challenges obtaining measurable and adequate numbers of outcomes, further delaying completion and increasing the cost of studies. Selection of study design, appropriate endpoints and validated outcome measures must consider the unique aspects of the disease for children (Box 9). Real-world data, patient registries and disease surveillance networks are increasingly used to support recruitment and conduct for Phase III trials.

Box 9. Outcomes and endpoint selection for children

Many outcome measures routinely used in adult trials have not been validated for children, and age-specific adaptations are often required. The following are key principles:

  • Select outcomes that are clinically meaningful to children and families.
  • Use age-appropriate, validated instruments.
  • Consider developmental stage when interpreting outcomes.
  • Use patient-reported or observer-reported outcomes to capture the child or caregiver perspective.

The use of validated, standardized outcome measures can save time and lead to more successful trial outcomes (see COMET resource).

Key resources

Phase III: Confirmatory efficacy and safety Phase III: Confirmatory efficacy and safety